Cough Desensitization Therapy for Cough Hypersensitivity Syndrome

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

November 30, 2020

Study Completion Date

February 13, 2021

Conditions
Cough
Interventions
BIOLOGICAL

Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer

Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through the Koko Digidoser nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. The concentration will never exceed 1000 micromolar. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.

BIOLOGICAL

Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer

Participants will be repeatedly exposed to a sub-threshold dose of aerosolized capsaicin through the KoKo Digidoser nebulizer during treatment sessions. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.

Trial Locations (1)

59812

University of Montana, Missoula

All Listed Sponsors
lead

University of Montana

OTHER

NCT04256733 - Cough Desensitization Therapy for Cough Hypersensitivity Syndrome | Biotech Hunter | Biotech Hunter